Logo image of PRTA

PROTHENA CORP PLC (PRTA) Stock Fundamental Analysis

NASDAQ:PRTA - Nasdaq - IE00B91XRN20 - Common Stock - Currency: USD

15.56  +0.31 (+2.03%)

After market: 15.56 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to PRTA. PRTA was compared to 572 industry peers in the Biotechnology industry. While PRTA has a great health rating, there are worries on its profitability. PRTA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PRTA has reported negative net income.
In the past year PRTA has reported a negative cash flow from operations.
In the past 5 years PRTA reported 4 times negative net income.
In the past 5 years PRTA reported 4 times negative operating cash flow.
PRTA Yearly Net Income VS EBIT VS OCF VS FCFPRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -22.15%, PRTA is doing good in the industry, outperforming 75.67% of the companies in the same industry.
Looking at the Return On Equity, with a value of -24.67%, PRTA belongs to the top of the industry, outperforming 82.06% of the companies in the same industry.
Industry RankSector Rank
ROA -22.15%
ROE -24.67%
ROIC N/A
ROA(3y)-8.51%
ROA(5y)-15.49%
ROE(3y)-10.2%
ROE(5y)-23.89%
ROIC(3y)N/A
ROIC(5y)N/A
PRTA Yearly ROA, ROE, ROICPRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTA Yearly Profit, Operating, Gross MarginsPRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRTA has more shares outstanding
Compared to 5 years ago, PRTA has more shares outstanding
PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRTA Yearly Shares OutstandingPRTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
PRTA Yearly Total Debt VS Total AssetsPRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

PRTA has an Altman-Z score of 5.91. This indicates that PRTA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PRTA (5.91) is better than 81.35% of its industry peers.
PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.91
ROIC/WACCN/A
WACC7.13%
PRTA Yearly LT Debt VS Equity VS FCFPRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

PRTA has a Current Ratio of 11.52. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 11.52, PRTA belongs to the best of the industry, outperforming 83.66% of the companies in the same industry.
A Quick Ratio of 11.52 indicates that PRTA has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 11.52, PRTA belongs to the best of the industry, outperforming 83.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.52
Quick Ratio 11.52
PRTA Yearly Current Assets VS Current LiabilitesPRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for PRTA have decreased strongly by -74.65% in the last year.
PRTA shows a decrease in Revenue. In the last year, the revenue decreased by -5.43%.
PRTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 146.70% yearly.
EPS 1Y (TTM)-74.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-389.47%
Revenue 1Y (TTM)-5.43%
Revenue growth 3Y366.5%
Revenue growth 5Y146.7%
Sales Q2Q%-98.86%

3.2 Future

Based on estimates for the next years, PRTA will show a very strong growth in Earnings Per Share. The EPS will grow by 23.74% on average per year.
The Revenue is expected to grow by 46.13% on average over the next years. This is a very strong growth
EPS Next Y18.51%
EPS Next 2Y-22.54%
EPS Next 3Y-9.97%
EPS Next 5Y23.74%
Revenue Next Year56.55%
Revenue Next 2Y-15.61%
Revenue Next 3Y13.76%
Revenue Next 5Y46.13%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PRTA Yearly Revenue VS EstimatesPRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
PRTA Yearly EPS VS EstimatesPRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30 40 50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTA Price Earnings VS Forward Price EarningsPRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTA Per share dataPRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

PRTA's earnings are expected to decrease with -9.97% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.54%
EPS Next 3Y-9.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTHENA CORP PLC

NASDAQ:PRTA (2/21/2025, 8:00:01 PM)

After market: 15.56 0 (0%)

15.56

+0.31 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners96.41%
Inst Owner Change6.6%
Ins Owners12.39%
Ins Owner Change0%
Market Cap837.28M
Analysts81.25
Price Target44.88 (188.43%)
Short Float %19.11%
Short Ratio17.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)110.98%
Min EPS beat(2)8.41%
Max EPS beat(2)213.55%
EPS beat(4)2
Avg EPS beat(4)52.77%
Min EPS beat(4)-9.36%
Max EPS beat(4)213.55%
EPS beat(8)5
Avg EPS beat(8)69.78%
EPS beat(12)5
Avg EPS beat(12)31.77%
EPS beat(16)6
Avg EPS beat(16)16.69%
Revenue beat(2)1
Avg Revenue beat(2)541.99%
Min Revenue beat(2)-22.4%
Max Revenue beat(2)1106.38%
Revenue beat(4)1
Avg Revenue beat(4)225.16%
Min Revenue beat(4)-97.74%
Max Revenue beat(4)1106.38%
Revenue beat(8)3
Avg Revenue beat(8)123.01%
Revenue beat(12)3
Avg Revenue beat(12)51.89%
Revenue beat(16)4
Avg Revenue beat(16)39.38%
PT rev (1m)-12.71%
PT rev (3m)-28.97%
EPS NQ rev (1m)-1.68%
EPS NQ rev (3m)-2.89%
EPS NY rev (1m)-0.83%
EPS NY rev (3m)4.11%
Revenue NQ rev (1m)-9.79%
Revenue NQ rev (3m)-33.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.28
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.57
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-4.2
Fwd EYN/A
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-2.85
OCFYN/A
SpS2.48
BVpS9.93
TBVpS9.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.15%
ROE -24.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.51%
ROA(5y)-15.49%
ROE(3y)-10.2%
ROE(5y)-23.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 196.11%
Cap/Sales 1.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.52
Quick Ratio 11.52
Altman-Z 5.91
F-Score2
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)138.92%
Cap/Depr(5y)93.18%
Cap/Sales(3y)1.41%
Cap/Sales(5y)19.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-389.47%
EPS Next Y18.51%
EPS Next 2Y-22.54%
EPS Next 3Y-9.97%
EPS Next 5Y23.74%
Revenue 1Y (TTM)-5.43%
Revenue growth 3Y366.5%
Revenue growth 5Y146.7%
Sales Q2Q%-98.86%
Revenue Next Year56.55%
Revenue Next 2Y-15.61%
Revenue Next 3Y13.76%
Revenue Next 5Y46.13%
EBIT growth 1Y-49.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.77%
EBIT Next 3Y-23.6%
EBIT Next 5YN/A
FCF growth 1Y-22.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.36%
OCF growth 3YN/A
OCF growth 5YN/A